Cargando…
Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs
BACKGROUND: Mycoplasma pneumoniae (Mpn) is a human pathogen that causes acute and chronic respiratory diseases and has been linked to many extrapulmonary diseases. Due to the lack of cell wall, Mpn is resistant to antibiotics targeting cell wall synthesis such as penicillin. During the last 10 years...
Autores principales: | Sun, Ren, Wang, Liya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750255/ https://www.ncbi.nlm.nih.gov/pubmed/23919755 http://dx.doi.org/10.1186/1471-2180-13-184 |
Ejemplares similares
-
Pan-Pathway Based Interaction Profiling of FDA-Approved Nucleoside and Nucleobase Analogs with Enzymes of the Human Nucleotide Metabolism
por: Egeblad, Louise, et al.
Publicado: (2012) -
Nucleoside Analogs with Fleximer Nucleobase
por: Chudinov, Mikhail V.
Publicado: (2020) -
Review on fluorinated nucleoside/non-nucleoside FDA-approved antiviral drugs
por: Ismail, Magda M. F., et al.
Publicado: (2022) -
Antiviral nucleoside analogs
por: Kataev, Vladimir E., et al.
Publicado: (2021) -
Improving properties of the nucleobase analogs T-705/T-1105 as potential antiviral
por: Jia, Xiao, et al.
Publicado: (2021)